Nusrat Jahan
About
Nusrat Jahan is from Greater Boston. Nusrat works in the following industries: "Research Services". Nusrat is currently Principal Scientist, Oncolytic Virus Discovery at Codagenix Inc., located in 238 Main Street, Cambridge, Massachusetts. In Nusrat's previous role as a Senior Scientist at Harvard Medical School and Massachusetts General Hospital, Nusrat worked in until Apr 2022. Prior to joining Harvard Medical School and Massachusetts General Hospital, Nusrat was a Research Scientist at Harvard Medical School and Massachusetts General Hospital and held the position of Research Scientist at Greater Boston Area. Prior to that, Nusrat was a Postdoctoral Research Fellow at Harvard Medical School and Massachusetts General Hospital, based in Greater Boston Area from Feb 2013 to Jan 2015. Nusrat started working as Doctoral and Postdoctoral Research Associate at Stony Brook University in Jan 2004. From Jan 2001 to Jan 2003, Nusrat was Graduate Research Assistant at University of Texas Health Science Center at Tyler.
Come check out Nusrat Jahan's email address on finalscout.com, a free professional database with 500 million business professionals and 200 million companies.
Nusrat Jahan's current jobs
Nusrat Jahan's past jobs
---Develop and implement independent research programs and interpret research experiments relating to brain tumor immunotherapy and immunovirotherapy ---Generation of next generation oncolytic viruses to be used for immunovirotherapy ---Study the efficacy of oncolytic viruses and cancer vaccine alone or in combination with immune check point inhibitors and/or agonist antibodies in orthotopic syngeneic mouse brain tumor models ---Functional studies to examine the immune response to different treatments (ELISA, ELISPOT assays, multi-color Flow-cytometry, IHC etc) ---Investigate, create, and develop new methods and technologies for research advancements ---Assist in laboratory management
My research was focused on developing novel oncolytic virus based therapies for resistant GBM and other difficult-to-treat cancers. I accomplished the following goals: 1)Identified the molecular mechanism for therapeutic resistance in brain tumors (IC50 determination, cell viability assays, signal transduction pathways, western blots, small molecule inhibition assays etc); 2) Established clinically relevant imageable mouse models for primary and recurrent brain tumors (orthotropic xenograft mouse models, tumor growth monitoring by BLI imaging etc); 3) Developed novel mechanism based oncolytic virus based therapies for primary and recurrent brain tumors (Kaplan-Meier curves, IHC, IF, in vivo BLI imaging etc); and 4) Developed different variants of oncolytic virus armed with immunomodulatory cytokines either alone or in combination with other therapeutic protein(s) for their future use in oncolytic immunotherapy against difficult-to-treat cancers (molecular cloning, recombinant virus construction, transfection, plaque purification, titration, concentration, etc.). The clinical significance: To provide new modalities for clinical management of primary brain tumors and brain metastases and other difficult-to-treat cancers.
(1) Engineering of poliovirus packaging cell lines as a vaccine platform for the production of trans-encapsidated replicons and assessment of immune response in CD155 transgenic mice to killed and live replicons. ----engineered poliovirus packaging cell lines (HeLa R19, HEK293, BHK, CHO, HT1080) that stably express high levels of the poliovirus capsid precursor (vector construction, transfection, clonal selection etc). ----used the engineered cell lines to produce trans-encapsulated replicons to be used as vaccines (viral RNA transfection, replicon titration, concentration and purification etc.). ----assessed the immune response to live and killed replicons in transgenic mouse model for poliovirus (administration of replicon vaccines in vivo, blood collection, antibody titration in serum, neutralization assays, etc.). 2) The study of Molecular Biology of poliovirus and poliovirus pathogenesis in laboratory CD155 transgenic mice using a chimeric oncolytic poliovirus, PV1(RIPO). ----Analyzed the growth phenotype of this recombinant oncolytic poliovirus in several neuronal and non-neuronal cells of human and mouse origin. ----Studied the pathogenesis of this recombinant oncolytic poliovirus in transgenic mouse model for poliovirus. ----Identified the molecular mechanisms associated with the growth defect of this virus in neuronal and mouse cells. 3) The study of the intracellular trafficking of poliovirus particles via transcytosis, and the directional release of viral particles (MDCK and CaCo2 as a cellular model).
Identified the regions in E. coli tmRNA required for binding of the ribosomal protein S1 RNA binding domain.